Clinicopathological and prognostic significance of survivin expression in renal cancer patients: a meta-analysis

Ma, Chengquan; Lu, Bingxin; Sun, E

doi:10.1136/postgradmedj-2016-134105

Cited by 8 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results show that high BIRC5 expression is associated with worse prognosis in all three analyzed types of kidney cancer. This is in line with previous results from a meta-analysis on 10 studies containing 1063 renal cancer cases, which demonstrated that high Survivin expression is associated with TNM stage and Fuhrman grade [ 54 ]. Other studies have also found a connection with more aggressive renal tumors and high Survivin expression [ 55 – 57 ].…”

Section: Discussionsupporting

confidence: 92%

Pan-cancer analysis identifies BIRC5 as a prognostic biomarker

et al. 2022

View full text Add to dashboard Cite

Background The BIRC5 gene encodes for the Survivin protein, which is a member of the inhibitor of apoptosis family. Survivin is found in humans during fetal development, but generally not in adult cells thereafter. Previous studies have shown that Survivin is abundant in most cancer cells, thereby making it a promising target for anti-cancer drugs and a potential prognostic tool. Methods To assess genetic alterations and mutations in the BIRC5 gene as well as BIRC5 co-expression with other genes, genomic and transcriptomic data were downloaded via cBioPortal for approximately 9000 samples from The Cancer Genome Atlas (TCGA) representing 33 different cancer types and 11 pan-cancer organ systems, and validated using the ICGC Data Portal and COSMIC. TCGA BIRC5 RNA sequencing data from 33 different cancer types and matching normal tissue samples for 16 cancer types were downloaded from Broad GDAC Firehose and validated using breast cancer microarray data from our previous work and data sets from the GENT2 web-based tool. Survival data were analyzed with multivariable Cox proportional hazards regression analysis and validated using KM plotter for breast-, ovarian-, lung- and gastric cancer. Results Although genetic alterations in BIRC5 were not common in cancer, BIRC5 expression was significantly higher in cancer tissue compared to normal tissue in the 16 different cancer types. For 14/33 cancer types, higher BIRC5 expression was linked to worse overall survival (OS, 4/14 after adjusting for both age and tumor grade and 10/14 after adjusting only for age). Interestingly, higher BIRC5 expression was associated with better OS in lung squamous cell carcinoma and ovarian serous cystadenocarcinoma. Higher BIRC5 expression was also linked to shorter progressive-free interval (PFI) for 14/33 cancer types (4/14 after adjusting for both age and tumor grade and 10/14 after adjusting only for age). External validation showed that high BIRC5 expression was significantly associated with worse OS for breast-, lung-, and gastric cancer. Conclusions Our findings suggest that BIRC5 overexpression is associated with the initiation and progression of several cancer types, and thereby a promising prognostic biomarker.

show abstract

Section: Discussionsupporting

confidence: 92%

Pan-cancer analysis identifies BIRC5 as a prognostic biomarker

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In RCC patients, BIRC5 has been identified as a prognostic biomarker for RCC survival in several studies evaluating the association between candidate gene expression and overall survival. The expression of BIRC5 was correlated with pathological grade and clinical stage and was also associated with the progression and poor survival of RCC patients [ 32 , 33 , 34 , 35 ]. Recently, a study examining the early diagnosis and prognostic value of BIRC5 in ccRCC based on Cancer Genome Atlas database and Human Protein Atlas database also showed that BIRC5 expression was significantly higher in ccRCC than in normal kidney tissue and correlated with the clinical stage and pathologic grade of ccRCC [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC

Hong,

Lee,

Jang

et al. 2023

IJMS

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the most common type of kidney cancer and includes more than 10 subtypes. Compared to the intensively investigated clear cell RCC (ccRCC), the underlying mechanisms and treatment options of other subtypes, including papillary RCC (pRCC) and chromogenic RCC (chRCC), are limited. In this study, we analyzed the public databases for ccRCC, pRCC, and chRCC and found that BIRC5 was commonly overexpressed in a large cohort of pRCC and chRCC patients as well as ccRCC and was closely related to the progression of RCCs. We investigated the potential of BIRC5 as a therapeutic target for these three types of RCCs. Loss and gain of function studies showed the critical role of BIRC5 in cancer growth. YM155, a BIRC5 inhibitor, induced a potent tumor-suppressive effect in the three types of RCC cells and xenograft models. To determine the mechanism underlying the anti-tumor effects of YM155, we examined epigenetic modifications in the BIRC5 promoter and found that histone H3 lysine 27 acetylation (H3K27Ac) was highly enriched on the promoter region of BIRC5. Chromatin-immunoprecipitation analysis revealed that H3K27Ac enrichment was significantly decreased by YM155. Immunohistochemistry of xenografted tissue showed that overexpression of BIRC5 plays an important role in malignancy in RCC. Furthermore, high expression of P300 was significantly associated with the progression of RCC. Our findings demonstrate the P300-H3K27Ac-BIRC5 cascade in three types of RCC and provide a therapeutic path for future research on RCC.

show abstract

“…In renal cell carcinoma patients, high BIRC5 expression was associated with increased TNM stage and high Fuhrman grade, which indicates that BIRC5 may be a good prognosis predictor (Ma et al, 2017). Furthermore, BIRC5 has been associated with tumor progression and chemoresistance to temsirolimus, an MTOR inhibitor.…”

Section: Kidney Cancermentioning

confidence: 99%

BIRC5 (baculoviral IAP repeat containing 5)

Branco¹,

Jimenez²,

Machado-Neto³

et al. 2019

Atlas of Genetics and Cytogenetics in Oncology and Haematology

View full text Add to dashboard Cite

BIRC5, also known as survivin, has been implicated in cell cycle progression and apoptosis avoidance. BIRC5 is highly expressed in embryonic tissues, however very low or absent in adult tissues. BIRC5 overexpression has been frequently associated to cancer development, a poor prognosis and chemoresistance. Besides that, different BIRC5 isoforms has been characterized and related to better or worse chemotherapy responses depending on the isoform and the cancer type. So far, many efforts have been conducted in order to deplete BIRC5 in cancer cells, including gene therapy, pharmacological and nanotechnological approaches. In this review, we will discuss the role of BIRC5 in cancer cell biology and its clinical significance, demonstrating its DNA/RNA and protein aspects, also its relevance for diagnosis and prognosis, and advances as a target for the treatment of different cancer types.

show abstract

Clinicopathological and prognostic significance of survivin expression in renal cancer patients: a meta-analysis

Abstract: Our results indicate that survivin is of prognostic signiﬁcance in patients with RCC.

Cited by 8 publications

References 39 publications

Pan-cancer analysis identifies BIRC5 as a prognostic biomarker

Pan-cancer analysis identifies BIRC5 as a prognostic biomarker

Therapeutic Efficacy of YM155 to Regulate an Epigenetic Enzyme in Major Subtypes of RCC

BIRC5 (baculoviral IAP repeat containing 5)

Contact Info

Product

Resources

About